Back to the WireSeeking Alpha
DevelopingSeeking Alpha ·
Regeneron, Alnylam win FDA nod for myasthenia gravis therapy
The FDA reportedly approved a myasthenia gravis therapy tied to Regeneron and Alnylam, according to the headline only. The item gives no further detail on the product or the companies' statements.
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.